Six major presentations covered virtually all aspects of the epidemiology of and for screening prostate carcinoma. Dr Richard Middleton, Professor and Chairman of the Department of Urology at the University of Utah, discussed the changing incidence and presentation of prostatic carcinoma. He derived the majority of the data presented in his talk from the Utah SEER (Surveillance, Epidemiology, and End Results) statistics. This highly respected cancer registry provided great insight into the changing incidence and prevalence of prostate cancer in the United States. There are 10 SEER registries throughout the US, of which Utah is one of the most highly regarded. Dr Middleton illustrated that in the National SEER registry, the incidence of prostate cancer peaked in 1992 in Caucasians, and a year later in African-Americans and subsequently has decreased (Figure 1) . Moreover, there has been a signi®cant decrease in more advanced prostate cancer since 1993 as illustrated in Figure 2 . Interestingly, we have previously reported that in Western Washington SEER registry, the incidence of prostate cancer peaked a year before the National SEER registry, undoubtedly owing to increased interest in prostate cancer in general and, particularly, early detection and screening in the Northwest.
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Dr Middleton provided additional information with respect to changing grade and stage of prostate cancer in the database. Table 1 , for example, demonstrates the changes in the grade at presentation, along with the incidence of nodal metastases known at the time of radical prostatectomy between 1988 and 1994. Interestingly, there is a slight increase in moderately differentiated prostatic carcinoma (Gleason score 4 ± 8) over these years, but a decrease in both well differentiated and poorly differentiated carcinoma. As there is no central pathologic review, some of these changes may be associated with different expertise in the utility of the Gleason grading system by local pathologists over this period. Of great interest, and widely recognized throughout the United States, is the changing incidence of nodal metastasis, where we see a staggering decrease over these six years. Clearly prostate carcinoma is presenting at an earlier stage and thus more men are potentially curable.
Dr Middleton went on to discuss a signi®cant problem in the literature: the relative paucity of data with Correspondence: Dr MK Brawer. meaningful long-term follow-up. He observed that a small fraction of the radical prostatectomy series has actual follow-up of more than 10 y. In addition to providing his series with long-term follow-up, Dr Middleton criticized the conclusions that have been generated by a number of authors with respect to actuarial projections of the effect of therapy when the real number of patients with long enough follow-up is so small. He observed, for example, that in most actuarial projection studies the variability with respect to treatment ef®cacy is greatest at the longest survival times where fewer patients have actually achieved this end-point.
Dr Middleton provided an update of his series of men with a minimum of 10 y follow-up following radical prostatectomy performed at the University of Utah and af®liated hospitals. Among 317 men, only 14 were lost to follow-up. The average length of follow-up was 11 y with a range of 10 ± 23 y. Dr Middleton observed that of those men with pathologic T1 or T2 disease, only 5 ± 6% died of prostate cancer over the 10 y follow-up. Unfortunately, he echoed the observation of others that PT3 and node positive men experienced a high rate of mortality from prostate carcinoma. The mean survival time for PT3 patients was 8.2 y and for N it was 7.5 y.
Dr Middleton expressed his concern of the lack of effective therapy for advanced prostate cancer. His two major topics,`The changing incidence of advanced disease' and`The promising outcome for those men with cancer detected early' provide certain impetus for the increased interest in early detection and screening. Of course, as was discussed in many of the subsequent sessions at the meeting, the problem with over-detection of clinically insigni®cant carcinoma remains.
Dr Powell, Professor in the Department of Urology at Wayne State University, and one of the leading experts on the issue of prostate cancer in the African-American, provided an insightful and highly thought-provoking discussion on this topic. Dr Powell reiterated the obvious, that prostatic carcinoma represents a signi®cantly greater problem in the African ± American men than others and offered some intriguing observations about why this may be. He introduced his discussion by attempting to de®ne African ± Americans and observing that there is no genetic basis and that there is considerable phenotypic heterogeneity. He observed, however, that this does represent a culture that shares a common (high-fat) diet, and that this may provide signi®cant explanation, at least in part, for the fact that prostate cancer is much more common in the African ± American and that there remains a three-time higher prostate cancer mortality.
Possible explanations for the differing mortality rate in stage and presentation between prostate cancer and African ± Americans and Caucasians include genetic and epigenetic phenomena. There may be differential growth rate owing to unknown differences in various growth factors, tumor suppresser genes, onco-genes, etc. There may be differences related to medical access, willingness to participate in early detection programs, etc. Finally, there may be unknown ethnic differences that may play a role.
Because of the potentially confounding variable of access to care, the reports of Fowler 2 4 is that prostatic intraepithelial neoplasia (PIN), the precursor to most carcinomas of the prostate, occurs more commonly at a younger age in African ± Americans than in Caucasians. If additional genetic`hits' occur in the African ± American at a younger age, this earlier initiating event (PIN), may progress to the invasive phenotype at a more rapid rate. Perhaps prostate cancer in the older African ± American more commonly exhibits a slower natural history, perhaps even slower than in Caucasians.
One potential problem associated with prostate cancer in African ± Americans is their relatively low rate of involvement in early detection and screening efforts ( Table 2) . Several barriers to early detection and screening suggested by Dr Powell included a potential feeling of distrust, concerns with respect to the digital rectal examination and diagnostic methods and general lack of knowledge of cancer (including potential bene®ts of early detection and therapy). Clearly, educational efforts must increase and Dr Powell's group is at the forefront in this domain. Dr Mettlin, lead Epidemiologist for the American Cancer Society Screening project and Chief of Epidemiology Research at Roswell Park Cancer Institute, offered an update on the American Cancer Society Screening project. The ACS National Prostate Cancer Detection Project (ACS ± NPCDP) is a multi-disciplinary investigation studying the yield of PSA, DRE and TRUS. Ten clinical centers evaluated a cohort of almost 3000 men for a period of eight years. There have been over 12000 patient evaluations and 1 290 biopsies. Two hundred and thirty three cancers have been detected (detection rate 7.8%) (233 out of 2999). The positive predictive value has been (18.1%) (233 out of 1290), with an average cancer detection rate of 2%. The highest rate was observed, as expected in the ®rst year (2.8%). By years seven and eight, the rate has fallen to well below 1%. 59.6% of patients elected radical prostatectomy and 23.9% radiation therapy. Dr Mettlin observed that approximately 1/3 of the cancers detected had occurred with a PSA less than 4 ng/mL and he utilized this observation to support the multi-modality approach invoked in this study. As we shall see, other investigators have suggested that by lowering the PSA cutoff, we can obviate the need for DRE and TRUS in the majority of settings without signi®cant loss of sensitivity.
Dr Mettlin provided interesting insight into the relative performance of diagnostic testing for prostate cancer compared to other common malignancies. Extending upon the work of Hulka et al 5 they observed that the performance of PSA alone, and particularly PSA in combination with digital rectal examination, provides signi®-cant overall test accuracy relative to detection of cervical, breast, colon or lung carcinoma (Table 3) . Moreover, Dr Mettlin provided the ®rst evidence that prostate cancer, early detection efforts, may be paying off by illustrating the decreasing mortality from prostate cancer between 1990 and 1995 as reported by the National Cancer Institute. 6 The United Kingdom has always taken a more conservative approach to early detection and screening, and indeed treatment, of clinically localized prostatic carcinoma. Paul Abrams, Consultant Urologist at Bristol University Hospital reported on`Screening for prostate cancer: The UK debate.' He introduced the concept by recognizing that throughout most of Europe and certainly in the United States, widespread efforts at early detection screening are in place. However, in the United Kingdom, the health service has made the proclamation that screening for prostate cancer should not be performed until careful assessment of the ef®cacy is demonstrated. Dr Abrams elected go through the classic screening requirements set forth by Wilson and Jungner who in 1990 de®ned the requirements for screening for any common disease. 7 Their criteria are summarized in Table 4 . Several of the classic criteria are met for prostate cancer. Obviously, prostate cancer is an important condition and facilities are widely available for diagnosis. There is a recognizable latent or early stage of disease, however, it is important to emphasize, as Dr Abrams did, that rarely does this provide symptoms and thus early detection efforts must be performed to identify these conditions. Dr Abrams questioned whether there was a suitable test for examination inviting concern of whether PSA alone is suf®cient by citing the ®ndings of the European randomized study of screening for prostate cancer where the incremental increase of ®nding cancer with DRE or TRUS was relatively small compared to what PSA alone provided.
Several of the Wilson ± Jungner criteria however, have not been de®nitively realized for prostate cancer, these were further discussed by Mr Abrams. There is no overall accepted treatment for recognized disease and novel therapy approaches, such as different ways of providing heat energy, cryotherapy, etc., also are being studied.
The natural history of prostate cancer in a given man is clearly not understood. We are only now beginning to gain some insight into the multitude of molecular events necessary for progression from the earliest precursor lesions (PIN) to the invasive or metastatic phenotype. The signi®cant heterogeneity expressed in prostate cancer represents a signi®cant stumbling block in this regard. Clearly we lack an agreed upon policy concerning who to treat. This essential Wilson ± Jungner criterion is extremely problematic with respect to prostate cancer. Until meaningful prognostic tests, which are applicable to the individual patient basis and obviate the heterogeneity expressed in prostate cancer are developed, we undoubtedly are treating many men whose carcinoma provides little signi®cant risk to them and, on the other hand, are offering locally directed therapy in other men whose carcinoma has already escaped the con®nes of the gland.
Obviously the economics associated with prostate cancer early detection screening and treatment are staggering. One could argue the signi®cance of this health care malady in af¯uent societies makes the cost justi®able. On a global basis, many other more signi®cant health care concerns would necessarily take precedent.
The National Health Service and Health Technology Assessment program emphasized, along with their recommendation that early detection and screening is not justi®ed, that there needs to be careful assessment of screening along with randomized clinical trials of aggressive treatment and watchful waiting, two such trials are underway in Scandinavia. The Prostate cancer Intervention Versus Observation Trial (PIVOT) in the United States, which randomizes men to radical prostatectomy versus watchful waiting, has accrued well with approximately 50% of the patients necessary for completion of the trial. Unfortunately, in all these studies it will be many years before the outcome is known. Indeed, Mr Abrams concluded his presentation with an argument that because the classic screening criteria of Wilson and Jungner have not all been met with respect to the prostate, it would be more sensible to extend our efforts at proving that our therapies for clinically localized prostate cancer are indeed effective. This could only be achieved by a randomized clinical trials.
Gunnar Aus, of Sahlgrenska University Hospital and one of the leading scholars of prostate cancer in Scandinavia, provided an interesting discussion of screening efforts in Sweden. This is a very appropriate setting for this investigation owing to the fact that Sweden has one of the highest mortalities from prostate cancer in the world. Because of this the Swedish government has conducted increased efforts at early detection and screening. Men aged 50 ± 65 y in Go È teborg, Sweden, have been randomized to active screening or a control group (10 000 men in the former, and 22 000 in the latter). The screening efforts begin with serum PSA determination. Those men with a level greater than 3.0 ng/mL, are invited to undergo a digital rectal examination, TRUS, and sextant biopsy. Out of 660 men with an elevated PSA, 611 actually underwent biopsy. Table 5 illustrates the signi®cant ®nd-ings from this investigation.
An intriguing observation from this study was the fact that while the detection rate increased as expected with age, the positive predictive value for PSA did not vary signi®cantly (Table 6 ).
Among the men with carcinoma, none had metastatic disease. 57% were T1c, 36% T2, and 7% T3-4. 7% of men had a Gleason score of 2 ± 4, 72% 5 ± 6, 19% Gleason 7, and 2% scored 8 ± 10. Another ®nding was the fact that among the 243 men with a PSA between 3.0 and 4.0 ng/mL, 32 (13.2%) were shown to have carcinoma representing 23% of all cancers detected. Further evidence that the screening effort was generally well accepted was the 60% attendance rate. Twelve percent of men would need biopsy with a PSA cutoff of 3.0 ng/mL. Twenty-two percent of men with a PSA greater than 3 ng/mL, were shown to have malignancy.
Fernand Labrie, Scienti®c Director of the Laval University Research Medical Center, Quebec, Canada, has made major contributions in a number of aspects of prostate carcinoma over the years. Dr Labrie, in this section, discussed the Canadian randomized screening trial for prostate carcinoma. In the design of this investigation, the observation in 1992 by Labrie that 3.0 ng/mL, represents the more appropriate PSA cutoff, was utilized. 8 Labrie noted that with a PSA greater than 3.0 ng/mL, the risk of prostate cancer in an initial screening evaluation is approximately 20%. In contrast, those with a PSA less than 3.0 ng/mL have a risk of approximately 1%. The algorithm used for detection of prostate cancer at Laval University is shown as Figure 3 . The predicted PSA is an attempt at adjusting the PSA for the volume of the gland (PSA density), which has been a subject of considerable controversy by a number of investigators.
In the Canadian randomized screening trial, 46 289 men between age 45 and 80 y who are registered in the electoral roles of Quebec City, were randomized in 1988 to screening or no screening. Among the 38 160 unscreened men, there were 138 prostate cancer-related deaths. In contrast, among the 8 129 men who were screened, there have been only six prostate cancer deaths. The annual death rates were 48.9 and 18.1 per 100 000 person years in the unscreened and screened groups respectively. Therefore, they have observed a 2.7-fold in favor of screening and early treatment, which was highly statistically signi®cant. While certainly there may be methodologic problems associated with the study, including actual duration of follow-up in the two populations, along with lead and length time bias issues, certainly these are promising data that would appear to support early detection and screening efforts.
Conclusion
The epidemiology and screening session provided important new insight into a number of aspects of prostate cancer. Many problems were addressed, however, signi®-cant controversy remains. All students of this disease, however, should be encouraged with the emerging data suggesting that we may be at the point of realizing major changes in the natural history of this most common human cancer.
